Compare Repligen Corporation Common Stock (RGEN) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs United Microelectronics Corp — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while United Microelectronics Corp trades at $20.54 (market cap $55.52B). The key difference: United Microelectronics Corp is far larger — about 5× Repligen Corporation Common Stock's market cap, and United Microelectronics Corp pays a 1.79% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and United Microelectronics Corp for 42 Days on average.
| RGEN | UMC | |
|---|---|---|
Market Cap | $11.14B | $55.52B |
Volume | 1,259,263 | 8,712,351 |
Sector | Health | Technology |
52-Week High | $194.57 | $28.02 |
52-Week Low | $102.87 | $7.02 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $11.02B | $52.61B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
UMC trades at $21.40, down 5.1% in the past 24 hours, with mixed technical signals showing a bearish moving average trend but oversold RSI conditions. Fundamentally, the company demonstrates strong profitability with 32.75% net income margin and has beaten earnings estimates for three consecutive quarters, though revenue growth remains modest at 2.3% year-over-year for 2025.
The stock presents a mixed outlook with strong earnings performance and attractive valuation metrics offset by slowing revenue growth and competitive pressures. Analyst sentiment leans cautious with a 'Hold' consensus, while technical indicators suggest potential near-term support around current levels given oversold conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
